CD274 and carcinoma: MC38wt (PD-L1high) and CT26wt (PD-L1low) carcinomas are responsive to anti-PD-L1 mAb therapy, whereas B16-F10wt (PD-L1high) and 4T1wt (PD-L1low) carcinomas show low-/nonresponsive behavior (Fig. S5A) [42], suggesting that the anti-PD-L1 mAb therapy response is independent of basal PD-L1 expression on cancer cells.